Related Experiment Videos
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid
N Feller1, M A van der Pol, A van Stijn
1Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
Leukemia
|June 18, 2004
Summary
Minimal residual disease (MRD) monitoring in acute myeloid leukaemia (AML) predicts patient relapse. Quantifying MRD in bone marrow and stem cell products accurately forecasts survival outcomes and aids in timely intervention strategies.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Minimal residual disease (MRD) is a key factor in acute myeloid leukaemia (AML) relapse.
- Immunophenotyping via flow cytometry is a standard method for MRD detection.
Purpose of the Study:
- To assess the predictive value of MRD quantification in AML patients undergoing chemotherapy.
- To correlate MRD levels in bone marrow and peripheral blood stem cell products with relapse-free survival.
Main Methods:
- MRD levels were quantified using flow cytometry in bone marrow samples from 72 AML patients after chemotherapy cycles.
- MRD was also assessed in autologous peripheral blood stem cell (PBSC) products.
- Statistical analysis correlated MRD percentages and absolute cell counts with relapse-free survival.
Main Results:
- MRD levels in bone marrow after chemotherapy cycles and in PBSC products strongly correlated with relapse-free survival.
- Higher MRD percentages (e.g., >1% after cycle 1, >0.11% after cycle 3) significantly increased the risk of relapse.
- Absolute MRD cell counts and post-treatment MRD increases also proved highly predictive of clinical outcomes.
Conclusions:
- MRD assessment at various stages of AML treatment is a reliable predictor of patient survival and impending relapses.
- Early detection and monitoring of MRD can inform treatment adjustments and improve patient management.
- Flow cytometry-based MRD quantification provides crucial prognostic information in AML.